Summary This paper describes a randomised clinical trial in patients with advanced breast cancer, comparing the regimen 3M, mitomycin C 7-8 mg m 2 (day 1), mitozantrone 7 -8 mg m-2 (day I and 21), methotrexate 35 mg m-2 (day 1 and 21) given on a 42 day cycle with a standard anthracycline containing regimen, VAC, vincristine 1.4 mg m-2 (day 1), anthracycline (adriamycin or epirubicin) 30 mg m-2 (day 1), cyclophosphamide 400 mg m-2 (day 1) given on a 21 day cycle. Of a total of 217 patients, 107 were randomised to 3M and 110 to VAC and a mean of 5.5 courses was given per patient. The Table 1. A total of 217 patients were entered into the study and after exclusions because of protocol violation (prior chemotherapy) there remained 106 patients who received 3M and 105 patients who received VAC. The median age was 55 (range 36-77) years for 3M and 58 (range 30-76) years for VAC. The median disease-free interval (primary diagnosis to first relapse) was similar for 3M (16 months) and VAC (15 months) and the median time from relapse to start of chemotherapy was also similar (8 months) for both regimens. Most patients (66% for both 3M and VAC) had received prior endocrine therapy consistent with our policy of using endocrine treatment for first relapse.
Patients with locally advanced or metastatic breast cancer who have failed endocrine treatment, or who have rapidly progressive disease, may be eligible for chemotherapy. Although combination chemotherapy using three or more cytotoxic drugs achieves objectives response rats of 50-60% (Canellos et al., 1976; Hoogstraten et al., 1976) there is little or no long term survival advantage using the drugs currently available (Canellos et al., 1976; Carbone et al., 1977; Powles et al., 1980) . Even with high dose chemotherapy the lack of substantial survival advantage makes the increased treatment related morbidity and mortality unacceptable (Rosner et al., 1987; Jones et al., 1987; Eder et al., 1986) . It is possible that aggressive chemotherapy for subsets of patients, perhaps younger patients with rapidly developing visceral disease, may have some survival benefit.
However, the main objective in the treatment of advanced breast cancer should be delay or palliation of disease related symptoms. This depends on sufficient dosage of drugs to achieve an objective response in most patients balanced against the toxicity related to treatment (Tannock et al., 1988) . The commonly used combination of vincristine, adriamycin and cyclophosphamide (VAC), using somewhat higher doses than we generally use, has been reported to give a 60% objective response rate in advanced breast cancer (Rainey et al., 1979) but with significant toxicity.
The alkylating agent mitomycin C and the anti-metabolite methotrexate both have single agent activity in breast cancer with low subjective toxicity (De Lena et al., 1982; van Oosterom et al., 1982; Carter, 1976) . However, when used in combination with melphalan (Perez et al., 1984) cumulative myelosuppression became a problem. Mitoxantrone (Novantrone [R] Lederle) is an anthracenedione which has equivalent activity to doxorubicin in advanced breast cancer, but with a lower incidence of nausea, vomiting and alopecia and also less cardiac toxicity (Cornbleet et al., 1984; Neidhart et al., 1983; Mouridsen et al., 1983) . We have developed a combination regimen 3M, comprising mitoxantrone, mitomycin C and methotrexate. In a pilot study this regimen gave a response rate of 60% with low objective toxicity (Powles et al., 1987 to the first course of chemotherapy. All visible lesions were photographed, and specific investigations to document tumour sites including chest X-ray, limited skeletal survey, liver ultrasound and CT scan (if appropriate) were performed. Whilst on treatment all patients were clinically assessed in out-patients before each course of chemotherapy together with a peripheral full blood count. Serum biochemistry, appropriate X-rays and other scans used in assessment were usually repeated after three cycles. Nadir counts (day 10-14) were obtained in those patients at particular risk of myelosuppression (e.g. prior radiotherapy). Patients were readmitted to the assessment unit in order to document response according to UICC criteria (Hayward et al., 1977) (Kaplan & Meier, 1958) and the log rank test (Peto et al., 1977) .
Results

Response
The response data are summarised in Table III. Of 211 patients randomised, 189 patients were assessable for response. The remaining 10% of patients were inassessable for response because of early deaths or inadequate follow-up. There was no significant difference in the overall response rate for 3M, 53% (95% CL 43-62%) and VAC 49% (95% CL 39-58%). Six patients in each arm achieved a complete remission. There was no difference in the assessable response rate for 3M (60%; 95% CL 50-70%) and VAC (54%; 95% CL 44-64%). The response rate by metastatic site was similar for both arms.
The response duration is shown in Figure 1 . There was no significant difference in the median duration of response which was 10 months (95% CL 6-15 months) for 3M and 11 months (95% CL 7-12 months) for VAC. Similarly there was no difference in survival from the start of treatment (Figure 2 ) which was 8 months (95% CL 6-12 months) for 3M and 10 months (95% CL 8-12 months) for VAC. The average actual drug doses given for the total 603 courses of 3M are summarised in Table IV Non-haematological toxicity for patients receiving 3M was low (Table V) and the main differences were the lack of significant neuropathy (P<0.001) and the reduction in alopecia (P<0.001). Fifty-four per cent of patients receiving VAC had alopecia >,grade 2, despite scalp cooling, compared with only 7% of patients receiving 3M. There was no difference in stomatitis between the two arms. Nausea and vomiting were analysed separately by individual courses using the toxicity grading system described above. Nausea (P<0.01) and vomiting (P<0.001) were significantly less for 3M compared with VAC. The data for haematological toxicity measured at day 21 (i.e. the time of next treatment) are presented in Table VI . The trend for myelosuppression was greater with 3M than VAC for all parameters (P<0.001) although the actual number of courses with grade 3/4 myelosuppression was low. In 90 patients who had nadir counts (day 10-14) because they were considered at special risk of myelosuppression (e.g. because of previous radiotherapy), there was no significant difference in myelosuppression (Table VII) . Systemic infection requiring parenteral antibiotics related to myelosuppression occurred in two patients receiving 3M and in five patients receiving VAC. There were no treatment related deaths.
Differences in myelosuppression after courses of 3M (with mitomycin C) and 2M (without mitomycin C) were compared by peripheral blood counts on days 21 (Table VIII) . There was significantly greater grade 3 and 4 leucopenia (P = <0.005) and thrombocytopenia (P = <0.01) following 3M than 2M courses.
Discussion
In this study of the use of first-line chemotherapy for metastatic breast cancer, the combination of mitomycin C, mitozantrone and methotrexate (3M) is as safe and effective as VAC but has significantly less subjective toxicity. There was no significant difference in the objective response rate, duration of remission or survival when 3M was compared to VAC and the response rate was similar to that reported for other non-intensive combinations (Canellos et al., 1976; Hoogstraten et al., 1976; Rainey et al., 1979; Cummings et al., 1985) . All patients had advanced local or metastatic disease at the time of starting chemotherapy and most had previously received endocrine therapy for relapse. Hence chemotherapy was given late in the natural history of metastatic breast cancer and this is reflected by the relatively short survival from the start of treatment (8 months for 3M and 10 months for VAC). In addition patients were not excluded on the basis of adverse survival features such as rapidly progressive disease, poor performance status or visceral disease. Comparisons of the survival data in this programme with that reported in other programmes when chemotherapy is used at first relapse or for minimal disease is therefore not valid.
Although general health dimensions were not assessed by quality of life assessments (Coates et al., 1987; Tannock et indicates that higher dosages of these drugs would not necessarily increase the response rate and might be associated with an increase in haematological toxicity.
In conclusion, this study indicates that this 3M combination of mitomycin C, mitozantrone and methotrexate is an effective regimen, with low subjective toxicity, for use as first-line chemotherapy in advanced breast cancer. Further comparison, including formal quality of life measurements with other standard regimens will give further indication of its palliative efficacy. The safety and low toxicity profile make 3M a possible chemotherapy option for clinical trials of adjuvant treatment or primary medical treatment of breast cancer.
